822:
Sy-Ortin, Teresa; Hohenberger, Peter; Baère, Thierry de; Cesne, Axel Le; Helfre, Sylvie; Saada-Bouzid, Esma; Borkowska, Aneta; Anghel, Rodica; Co, Ann; Gebhart, Michael; Kantor, Guy; Montero, Angel; Loong, Herbert H; Vergés, Ramona; Lapeire, Lore; Dema, Sorin; Kacso, Gabriel; Austen, Lyn; Moureau-Zabotto, Laurence; Servois, Vincent; Wardelmann, Eva; Terrier, Philippe; Lazar, Alexander J; Bovée, Judith V M G; Péchoux, Cécile Le; Papai, Zsusanna (2019-08-01).
203:. In 2011, Nanobiotix treated its first patient using NBTXR3. In 2018 the results of a phase III clinical trial established that this new type of product could work in humans. In 2019 the company received approval to sell NBTXR3 in Europe under the brand name Hensify® for the treatment of soft tissue sarcomas of the extremities and trunk wall. In 2015 Levy joined the board of biotech
31:
896:
Bonvalot, Sylvie; Le
Pechoux, CĂ©cile; De Baere, Thierry; Kantor, Guy; Buy, Xavier; Stoeckle, Eberhard; Terrier, Philippe; Sargos, Paul; Coindre, Jean Michel; Lassau, Nathalie; Ait Sarkouh, Rafik; Dimitriu, Mikaela; Borghi, Elsa; Levy, Laurent; Deutsch, Eric; Soria, Jean-Charles (2016-12-22).
821:
Bonvalot, Sylvie; Rutkowski, Piotr L; Thariat, Juliette; Carrère, Sébastien; Ducassou, Anne; Sunyach, Marie-Pierre; Agoston, Peter; Hong, Angela; Mervoyer, Augustin; Rastrelli, Marco; Moreno, Victor; Li, Rubi K; Tiangco, Béatrice; Herraez, Antonio Casado; Gronchi, Alessandro; Mangel, László;
238:(ETPN) in 2012 and was elected vice president. Levy is a founding member of the ETPN Translation Advisory Board, which has supported 109 European biotech entrepreneurs in launching their companies. Levy also helped to establish the ETPN's Nanomedicine Translation Hub, which advises
190:
In 2003, Levy founded
Nanobiotix to create a medical treatment using the techniques he developed at SUNY Buffalo. Nanobiotix would build on his work to develop what is now known as NBTXR3, a first-in-class “radioenhancer” designed to significantly increase the efficacy of
457:
Bergey, Earl J.; Levy, Laurent; Wang, Xiaopeng; Krebs, Linda J.; Lal, Manjari; Kim, Kyoung-Soo; Pakatchi, Shadi; Liebow, Charles; Prasad, Paras N. (2002). "DC Magnetic Field
Induced Magnetocytolysis of Cancer Cells Targeted by LH-RH Magnetic Nanoparticles in vitro".
824:"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial"
685:
Levy, L.; Feltin, N.; Ingert, D.; Pileni, M. P. (1997). "Three
Dimensionally Diluted Magnetic Semiconductor Clusters Cd1-yMnyS with a Range of Sizes and Compositions: Dependence of Spectroscopic Properties on the Synthesis Mode".
988:
390:
Levy, Laurent; Sahoo, Yudhisthira; Kim, Kyoung-Soo; Bergey, Earl J.; Prasad, Paras N. (2002). "Nanochemistry: Synthesis and
Characterization of Multifunctional Nanoclinics for Biological Applications".
420:
Maggiorella, Laurence; Barouch, Gilles; Devaux, Corinne; Pottier, Agnès; Deutsch, Eric; Bourhis, Jean; Borghi, Elsa; Levy, Laurent (2012). "Nanoscale radiotherapy with hafnium oxide nanoparticles".
168:
939:
1062:
Pottier, Agnès; Levy, Laurent; Bergere, Maxime; Mpambani, Francis; Berjaud, Céline; Paolini, Marion; Poul, Laurence; Meyre, Marie-Edith; Germain, Matthieu (19 March 2018).
160:
then to physics and chemistry after two years, graduating with his bachelor's degree in 1994. He then earned his master's degree (DEA) in physics of condensed matter from
1340:
171:
for doctoral studies in physical chemistry, specializing in nanomaterials. His doctoral thesis centered on quantum confinement as it relates to magnetic semiconductors.
1304:
575:
899:"First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas"
1350:
650:
Levy, L.; Hochepied, J. F.; Pileni, M. P. (1996). "Control of the Size and
Composition of Three Dimensionally Diluted Magnetic Semiconductor Clusters".
989:"VALBIOTIS Announces Positive Results From the Phase IIA Clinical Study of VALEDIA®, Now the First Product Proven Effective in People With Prediabetes"
235:
772:
1282:
218:
In 2019, Levy co-founded the biotechnology company
Curadigm as a spin-off from Nanobiotix. Curadigm's lead technology is a nanoprimer that affects
129:(CEO) since its inception in March 2003. He also authored more than 35 international scientific publications and has applied for several patents.
230:
As
Nanobiotix grew, Levy became increasingly frustrated at the struggles nanomedicine companies faced in gaining visibility and support in the
1370:
239:
1355:
1335:
358:
PHARMACEUTICAL COMPOSITION COMBINING AT LEAST TWO DISTINCT NANOPARTICLES AND A PHARMACEUTICAL COMPOUND, PREPARATION AND USES THEREOF
161:
153:
59:
377:
372:
367:
362:
357:
352:
347:
1345:
1038:
146:
44:
525:
1064:"Priming the body to receive the therapeutic agent to redefine treatment benefit/risk profile - Scientific Reports"
126:
1365:
780:
1258:
1156:"Improving the translation in Europe of nanomedicines (a.k.a. drug delivery) from academia to industry"
342:
337:
332:
327:
322:
317:
307:
302:
550:
1360:
872:
63:
940:"Potential benefits of adding radioenhancer nanoparticles to RT treatment for soft-tissue sarcoma"
483:
323:
INORGANIC NANOPARTICLES COMPOSITIONS IN COMBINATION WITH IONIZING RADIATIONS FOR TREATING CANCER
242:, Startups, Academics and Inventors on how to bring their nanomedicine projects to the market.
1175:
1136:
1128:
1093:
920:
853:
845:
795:
703:
667:
475:
445:
437:
408:
211:
based on clinical findings. The company develops nutraceutical products for the prevention of
192:
67:
1213:
1167:
1120:
1083:
1075:
910:
835:
695:
659:
467:
429:
400:
174:
Following the receipt of his doctorate, Levy completed a postdoctoral fellowship with Prof.
106:
318:
NANOPARTICLES COMPRISING METALLIC AND HAFNIUM OXIDE MATERIALS, PREPARATION AND USES THEREOF
222:
function, reducing its ability to filter out drugs, making drug delivery more efficacious.
807:
175:
746:
1088:
1063:
509:
231:
114:
840:
823:
1329:
1155:
487:
208:
103:
312:
196:
179:
118:
72:
1171:
915:
898:
338:
PHARMACEUTICAL COMPOSITION COMPRISING NANOPARTICLES, PREPARATION AND USES THEREOF
280:
2003 Inventor of the year: Niagara frontier intellectual property law association
1079:
471:
373:
COATED NANOPARTICLES FOR USE FOR MODULATING ELECTRICAL POLARIZATION OF NEURONS
290:
157:
122:
91:
1132:
1111:
LĂ©vy, Laurent (2014). "Europe as leaders in nanomedicine: let's go for it!".
849:
707:
671:
479:
441:
412:
368:
NANOPARTICLES FOR USE FOR ENHANCING BRAIN PERFORMANCES OR FOR TREATING STRESS
200:
1179:
1140:
1097:
924:
857:
449:
30:
1305:"Dr. Laurent Levy, CEO of Nanobiotix, Receives UB Entrepreneurship Award"
721:
625:
600:
576:"Dr. Laurent Levy, CEO of Nanobiotix, Receives UB Entrepreneurship Award"
353:
WO/2014/191569: PHARMACEUTICAL COMPOSITION, PREPARATION AND USES THEREOF
212:
110:
274:
2013 University of
Buffalo Young Entrepreneurs Prize : Laurent Levy
204:
1218:
1201:
1124:
699:
663:
433:
404:
257:
CPhI Pharma Award - Excellence in Pharma: CEO of the year
Laurent Levy
142:
48:
1283:"Nanotech company Nanobiotix earns Prix Galien Award for innovation"
219:
138:
747:"UB spinoff Nanobiotix looks to bring cancer treatment to market"
963:
260:
CPhI Pharma Award - Pharma Company of the year : Nanobiotix
60:
Pierre and Marie Curie University, now Paris-Sorbonne University
551:"Interview with Laurent Levy, CEO of Nanobiotix - BioFIT 2020"
87:
76:
215:
in pre-diabetics. Levy helped take Valbiotis public in 2018.
1233:
1013:
263:
European Business Award 2018 : The award for Innovation
178:
at the Institute for Lasers, Photonics, and Biophotonics at
313:
NANOPARTICLE DELIVERY SYSTEMS, PREPARATION AND USES THEREOF
234:. To advocate for nanomedical development, Levy joined the
121:. He is the co-founder of the global biotechnology company
137:
Laurent Levy was born on the outskirts of northern-east
466:(4). Springer Science and Business Media LLC: 293–299.
152:
After high school, Laurent went on to study biology at
378:
NANOPARTICLES FOR USE FOR TREATING A NEURONAL DISORDER
363:
NANOPARTICLES FOR USE FOR TREATING A NEURONAL DISORDER
268:
2016 European Mediscience Award: Best technology Award
328:
COMPOSITIONS AND METHODS FOR USE IN MEDICAL DIAGNOSIS
1039:"New Nanobiotix subsidiary to use 'nanoprimer' tech"
658:(47). American Chemical Society (ACS): 18322–18326.
348:
METALLIC NANOPARTICLES, PREPARATION AND USES THEREOF
873:"Novel Radioenhancer Boosts RT Response in Sarcoma"
526:"Interview: Laurent Levy – CEO, Nanobiotix, France"
83:
55:
37:
21:
694:(45). American Chemical Society (ACS): 9153–9160.
1202:"Improving Innovation in Nano-Healthcare Funding"
399:(9). American Chemical Society (ACS): 3715–3721.
343:NANOPARTICLES FOR USE AS A THERAPEUTIC VACCINE
1014:"Together to Reshape Healthcare Full Version"
8:
333:COMPOSITIONS AND METHODS FOR USE IN ONCOLOGY
154:Pierre and Marie Curie University (Paris VI)
207:Valbiotis, the first company to register a
1285:. Applied Radiation Oncology. Dec 17, 2019
29:
18:
1309:Applied Sciences from Technology Networks
1217:
1087:
914:
839:
580:Applied Sciences from Technology Networks
236:European Technology Platform Nanomedicine
1341:Pierre and Marie Curie University alumni
501:
803:
793:
428:(9). Future Medicine Ltd: 1167–1181.
271:2015 Prix de la relation actionnaires
7:
964:"Research & Development Company"
1119:(4). Future Medicine Ltd: 389–391.
688:The Journal of Physical Chemistry B
1351:French healthcare chief executives
167:Laurent attended Paris VI and the
156:. He changed his area of study to
14:
1154:Eaton, Michael A.W. (June 2012).
652:The Journal of Physical Chemistry
16:French Scientist and Entrepreneur
1263:The Nanomedicine Translation Hub
771:Reuters Editorial (2020-03-05).
226:European nanomedicine advocacy
1:
1172:10.1016/j.jconrel.2012.06.016
1160:Journal of Controlled Release
916:10.1158/1078-0432.CCR-16-1297
841:10.1016/S1470-2045(19)30326-2
1371:University at Buffalo alumni
195:without increasing negative
871:Swift, Diana (2019-07-16).
1387:
1200:Eaton, Mike (March 2018).
1080:10.1038/s41598-018-23140-9
944:Applied Radiation Oncology
773:"Officer Profile - Quotes"
630:The Wall Street Transcript
303:NANOBIOTIX CORE TECHNOLOGY
28:
1356:French nanotechnologists
1336:French physical chemists
903:Clinical Cancer Research
133:Early life and education
1346:French chief executives
472:10.1023/a:1020906307053
460:Biomedical Microdevices
127:chief executive officer
1206:Precision Nanomedicine
393:Chemistry of Materials
246:Awards and recognition
182:in the United States.
751:University at Buffalo
308:ACTIVATABLE PARTICLES
277:2006 Paris Bio Prize
125:, and has served as
828:The Lancet Oncology
1068:Scientific Reports
806:has generic name (
1219:10.29016/180108.1
1125:10.2217/nnm.14.14
1043:The Pharma Letter
938:Cynthia E. Keen.
700:10.1021/jp970978r
664:10.1021/jp960824w
514:The Pharma Letter
434:10.2217/fon.12.96
405:10.1021/cm0203013
193:radiation therapy
113:, and pioneer of
102:(born 1971) is a
97:
96:
1378:
1320:
1319:
1317:
1316:
1301:
1295:
1294:
1292:
1290:
1279:
1273:
1272:
1270:
1269:
1255:
1249:
1248:
1246:
1245:
1230:
1224:
1223:
1221:
1197:
1191:
1190:
1188:
1186:
1151:
1145:
1144:
1108:
1102:
1101:
1091:
1059:
1053:
1052:
1050:
1049:
1035:
1029:
1028:
1026:
1025:
1010:
1004:
1003:
1001:
1000:
985:
979:
978:
976:
975:
960:
954:
953:
951:
950:
935:
929:
928:
918:
893:
887:
886:
884:
883:
868:
862:
861:
843:
834:(8): 1148–1159.
818:
812:
811:
805:
801:
799:
791:
789:
788:
779:. Archived from
768:
762:
761:
759:
758:
743:
737:
736:
734:
733:
722:"The management"
718:
712:
711:
682:
676:
675:
647:
641:
640:
638:
637:
622:
616:
615:
613:
612:
601:"The management"
597:
591:
590:
588:
587:
572:
566:
565:
563:
562:
547:
541:
540:
538:
537:
523:
521:
520:
506:
491:
453:
416:
251:2019 Prix Galien
199:associated with
107:physical chemist
33:
19:
1386:
1385:
1381:
1380:
1379:
1377:
1376:
1375:
1326:
1325:
1324:
1323:
1314:
1312:
1303:
1302:
1298:
1288:
1286:
1281:
1280:
1276:
1267:
1265:
1257:
1256:
1252:
1243:
1241:
1234:"HealthtechTAB"
1232:
1231:
1227:
1199:
1198:
1194:
1184:
1182:
1153:
1152:
1148:
1110:
1109:
1105:
1061:
1060:
1056:
1047:
1045:
1037:
1036:
1032:
1023:
1021:
1012:
1011:
1007:
998:
996:
987:
986:
982:
973:
971:
962:
961:
957:
948:
946:
937:
936:
932:
895:
894:
890:
881:
879:
870:
869:
865:
820:
819:
815:
802:
792:
786:
784:
770:
769:
765:
756:
754:
745:
744:
740:
731:
729:
720:
719:
715:
684:
683:
679:
649:
648:
644:
635:
633:
626:"Levy, Laurent"
624:
623:
619:
610:
608:
599:
598:
594:
585:
583:
574:
573:
569:
560:
558:
549:
548:
544:
535:
533:
530:PharmaBoardroom
524:
518:
516:
508:
507:
503:
498:
456:
422:Future Oncology
419:
389:
386:
299:
287:
248:
228:
188:
176:Paras N. Prasad
135:
71:
51:
42:
24:
17:
12:
11:
5:
1384:
1382:
1374:
1373:
1368:
1363:
1358:
1353:
1348:
1343:
1338:
1328:
1327:
1322:
1321:
1296:
1274:
1250:
1225:
1192:
1166:(3): 370–371.
1146:
1103:
1054:
1030:
1005:
980:
955:
930:
909:(4): 908–917.
888:
863:
813:
763:
738:
713:
677:
642:
617:
592:
567:
542:
510:"Laurent Levy"
500:
499:
497:
494:
493:
492:
454:
417:
385:
382:
381:
380:
375:
370:
365:
360:
355:
350:
345:
340:
335:
330:
325:
320:
315:
310:
305:
298:
295:
294:
293:
286:
285:External links
283:
282:
281:
278:
275:
272:
269:
266:
265:
264:
261:
258:
252:
247:
244:
232:European Union
227:
224:
187:
184:
134:
131:
115:nanotechnology
95:
94:
85:
81:
80:
57:
53:
52:
43:
39:
35:
34:
26:
25:
22:
15:
13:
10:
9:
6:
4:
3:
2:
1383:
1372:
1369:
1367:
1366:Living people
1364:
1362:
1359:
1357:
1354:
1352:
1349:
1347:
1344:
1342:
1339:
1337:
1334:
1333:
1331:
1310:
1306:
1300:
1297:
1284:
1278:
1275:
1264:
1260:
1254:
1251:
1239:
1238:HealthtechTAB
1235:
1229:
1226:
1220:
1215:
1211:
1207:
1203:
1196:
1193:
1181:
1177:
1173:
1169:
1165:
1161:
1157:
1150:
1147:
1142:
1138:
1134:
1130:
1126:
1122:
1118:
1114:
1107:
1104:
1099:
1095:
1090:
1085:
1081:
1077:
1073:
1069:
1065:
1058:
1055:
1044:
1040:
1034:
1031:
1019:
1015:
1009:
1006:
994:
990:
984:
981:
969:
965:
959:
956:
945:
941:
934:
931:
926:
922:
917:
912:
908:
904:
900:
892:
889:
878:
877:MedPage Today
874:
867:
864:
859:
855:
851:
847:
842:
837:
833:
829:
825:
817:
814:
809:
804:|author=
797:
783:on 2020-03-23
782:
778:
774:
767:
764:
752:
748:
742:
739:
727:
723:
717:
714:
709:
705:
701:
697:
693:
689:
681:
678:
673:
669:
665:
661:
657:
653:
646:
643:
631:
627:
621:
618:
606:
602:
596:
593:
581:
577:
571:
568:
556:
552:
546:
543:
531:
527:
515:
511:
505:
502:
495:
489:
485:
481:
477:
473:
469:
465:
461:
455:
451:
447:
443:
439:
435:
431:
427:
423:
418:
414:
410:
406:
402:
398:
394:
388:
387:
383:
379:
376:
374:
371:
369:
366:
364:
361:
359:
356:
354:
351:
349:
346:
344:
341:
339:
336:
334:
331:
329:
326:
324:
321:
319:
316:
314:
311:
309:
306:
304:
301:
300:
296:
292:
289:
288:
284:
279:
276:
273:
270:
267:
262:
259:
256:
255:
253:
250:
249:
245:
243:
241:
237:
233:
225:
223:
221:
216:
214:
210:
209:nutraceutical
206:
202:
198:
194:
185:
183:
181:
177:
172:
170:
165:
163:
159:
155:
150:
148:
144:
140:
132:
130:
128:
124:
120:
116:
112:
108:
105:
101:
93:
89:
86:
82:
78:
74:
69:
65:
61:
58:
54:
50:
46:
40:
36:
32:
27:
20:
1313:. Retrieved
1311:. 2013-04-04
1308:
1299:
1287:. Retrieved
1277:
1266:. Retrieved
1262:
1253:
1242:. Retrieved
1240:. 2019-10-11
1237:
1228:
1209:
1205:
1195:
1183:. Retrieved
1163:
1159:
1149:
1116:
1113:Nanomedicine
1112:
1106:
1071:
1067:
1057:
1046:. Retrieved
1042:
1033:
1022:. Retrieved
1020:. 2019-05-17
1017:
1008:
997:. Retrieved
995:. 2019-07-03
992:
983:
972:. Retrieved
970:. 2018-07-31
967:
958:
947:. Retrieved
943:
933:
906:
902:
891:
880:. Retrieved
876:
866:
831:
827:
816:
785:. Retrieved
781:the original
776:
766:
755:. Retrieved
753:. 2014-05-23
750:
741:
730:. Retrieved
728:. 2019-02-28
725:
716:
691:
687:
680:
655:
651:
645:
634:. Retrieved
632:. 2020-03-20
629:
620:
609:. Retrieved
607:. 2019-02-28
604:
595:
584:. Retrieved
582:. 2013-04-04
579:
570:
559:. Retrieved
557:. 2016-11-08
554:
545:
534:. Retrieved
532:. 2017-06-13
529:
517:. Retrieved
513:
504:
463:
459:
425:
421:
396:
392:
384:Publications
229:
217:
197:side effects
189:
180:SUNY Buffalo
173:
166:
151:
136:
119:nanomedicine
100:Laurent Levy
99:
98:
73:SUNY Buffalo
23:Laurent Levy
1361:1971 births
1074:(1): 4797.
555:BioFIT 2020
1330:Categories
1315:2020-03-05
1268:2020-03-05
1244:2020-03-05
1048:2020-03-05
1024:2020-03-05
999:2020-03-05
974:2020-03-05
949:2020-03-05
882:2020-03-05
787:2020-03-06
757:2020-03-06
732:2020-03-06
726:Nanobiotix
636:2020-06-17
611:2020-03-05
605:Nanobiotix
586:2020-03-05
561:2020-03-05
536:2020-03-05
519:2020-03-05
496:References
162:UPVI-ESPCI
158:biophysics
123:Nanobiotix
92:Nanobiotix
84:Occupation
1133:1743-5889
968:Valbiotis
850:1470-2045
708:1520-6106
672:0022-3654
488:134380514
480:1387-2176
442:1479-6694
413:0897-4756
201:radiation
147:Montreuil
56:Education
45:Montreuil
1180:22721816
1141:24787438
1098:29556068
1018:Curadigm
993:BioSpace
925:27998887
858:31296491
796:cite web
450:23030491
291:Ted Talk
213:diabetes
111:inventor
1289:5 March
1185:5 March
1089:5859131
297:Patents
205:startup
1259:"ETPN"
1178:
1139:
1131:
1096:
1086:
923:
856:
848:
706:
670:
486:
478:
448:
440:
411:
143:France
104:French
49:France
484:S2CID
254:2018
220:liver
145:, in
139:Paris
1291:2020
1187:2020
1176:PMID
1137:PMID
1129:ISSN
1094:PMID
921:PMID
854:PMID
846:ISSN
808:help
704:ISSN
668:ISSN
476:ISSN
446:PMID
438:ISSN
409:ISSN
240:SMEs
186:Work
117:and
41:1971
38:Born
1214:doi
1168:doi
1164:164
1121:doi
1084:PMC
1076:doi
911:doi
836:doi
696:doi
692:101
660:doi
656:100
468:doi
430:doi
401:doi
169:CEA
90:of
88:CEO
77:PhD
1332::
1307:.
1261:.
1236:.
1212:.
1208:.
1204:.
1174:.
1162:.
1158:.
1135:.
1127:.
1115:.
1092:.
1082:.
1070:.
1066:.
1041:.
1016:.
991:.
966:.
942:.
919:.
907:23
905:.
901:.
875:.
852:.
844:.
832:20
830:.
826:.
800::
798:}}
794:{{
777:IN
775:.
749:.
724:.
702:.
690:.
666:.
654:.
628:.
603:.
578:.
553:.
528:.
512:.
482:.
474:.
462:.
444:.
436:.
424:.
407:.
397:14
395:.
164:.
149:.
141:,
109:,
68:MS
66:,
64:BS
47:,
1318:.
1293:.
1271:.
1247:.
1222:.
1216::
1210:1
1189:.
1170::
1143:.
1123::
1117:9
1100:.
1078::
1072:8
1051:.
1027:.
1002:.
977:.
952:.
927:.
913::
885:.
860:.
838::
810:)
790:.
760:.
735:.
710:.
698::
674:.
662::
639:.
614:.
589:.
564:.
539:.
522:.
490:.
470::
464:4
452:.
432::
426:8
415:.
403::
79:)
75:(
70:)
62:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
